LEADER 05643nam 2200769Ia 450 001 9910816988403321 005 20200520144314.0 010 $a9786612368295 010 $a9781282368293 010 $a128236829X 010 $a9780470447796 010 $a0470447796 010 $a9780470447789 010 $a0470447788 035 $a(CKB)1000000000821972 035 $a(EBL)468703 035 $a(OCoLC)609847438 035 $a(SSID)ssj0000293143 035 $a(PQKBManifestationID)11229735 035 $a(PQKBTitleCode)TC0000293143 035 $a(PQKBWorkID)10274589 035 $a(PQKB)10166782 035 $a(MiAaPQ)EBC468703 035 $a(Au-PeEL)EBL468703 035 $a(CaPaEBR)ebr10346093 035 $a(CaONFJC)MIL236829 035 $a(OCoLC)749131244 035 $a(FINmELB)ELB178989 035 $a(Perlego)2756312 035 $a(EXLCZ)991000000000821972 100 $a20080929d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCrystallization of organic compounds $ean industrial perspective /$fHsien-Hsin Tung ... [et al.] 205 $a1st ed. 210 $aHoboken, N.J. $cWiley$dc2009 215 $a1 online resource (304 p.) 300 $aDescription based upon print version of record. 311 08$a9780471467809 311 08$a0471467804 320 $aIncludes bibliographical references and index. 327 $aCrystallization of Organic Compounds; Contents; Preface; 1. Introduction to Crystallization Issues; 1.1 Crystal Properties and Polymorphism (Chapters 2 and 3); 1.2 Nucleation and Growth Kinetics (Chapter 4); 1.3 Critical Issues (Chapter 5); 1.4 Mixing and Crystallization (Chapter 6); 1.5 Crystallization Process Options (Chapters 7-10); 1.6 Special Applications (Chapter 11); 1.7 Regulatory Issues; 2. Properties; 2.1 Solubility; 2.2 Supersaturation, Metastable Zone, and Induction Time; 2.3 Oil, Amorphous, and Crystalline States; 2.4 Polymorphism; 2.5 Solvate 327 $a2.6 Solid Compound, Solid Solution, and Solid Mixture2.7 Inclusion and Occlusion; 2.8 Adsorption, Hygroscopicity, and Deliquescence; 2.9 Crystal Morphology; 2.10 Particle Size Distribution and Surface Area; 3. Polymorphism; 3.1 Phase Rule; 3.2 Phase Transition; 3.3 Examples; Example 3-1 Indomethacin; Example 3-2 Sulindac; Example 3-3 Losartan; Example 3-4 Finasteride; Example 3-5 Ibuprofen Lysinate; Example 3-6 HCl Salt of a Drug Candidate; Example 3-7 Second HCl Salt of a Drug Candidate; Example 3-8 Prednisolone t-Butylacetate; Example 3-9 Phthalylsulfathiazole; 3.4 Future Direction 327 $a4. Kinetics4.1 Supersaturation and Rate Processes; 4.2 Nucleation; 4.3 Crystal Growth; 4.4 Nucleate/Seed Aging and Ostwald Ripening; 4.5 Delivered Product: Size Distribution and Morphology; 5. Critical Issues in Crystallization Practice; 5.1 Introduction; 5.2 Nucleation; 5.3 Growth; 5.4 Oiling Out, Agglomeration/Aggregation; 5.5 Seeding; 5.6 Rate of Generation of Supersaturation; 5.7 Summary of Critical Issues; 6. Mixing and Crystallization; 6.1 Introduction; 6.2 Mixing Considerations; 6.3 Mixing Effects on Nucleation; 6.4 Mixing Effects on Crystal Growth; 6.5 Mixing Scale-up 327 $a6.6 Crystallization EquipmentExample 6-1; 7. Cooling Crystallization; 7.1 Batch Operation; 7.2 Continuous Operations; 7.3 Process Design-Examples; Example 7-1 Intermediate in a Multistep Synthesis; Example 7-2 Pure Crystallization of an API; Example 7-3 Crystallization Using the Heel from the Previous Batch as Seed; Example 7-4 Resolution of Ibuprofen Via Stereospecific Crystallization; Example 7-5 Crystallization of Pure Bulk with Polymorphism; Example 7-6 Continuous Separation of Stereoisomers; 8. Evaporative Crystallization; 8.1 Introduction; 8.2 Solubility Diagrams 327 $a8.3 Factors Affecting Nucleation and Growth8.4 Scale-up; 8.5 Equipment; Example 8-1 Crystallization of a Pharmaceutical Intermediate Salt; Example 8-2 Crystallization of the Sodium Salt of a Drug Candidate; 9. Antisolvent Crystallization; 9.1 Semibatch Operation; Example 9-1 Crystallization of an Intermediate; Example 9-2 Rejection of Isomeric Impurities of Final Bulk Active Product; Example 9-3 Crystallization of a Pharmaceutical Product with Poor Nucleation and Growth Characteristics; Example 9-4 Impact of Solvent and Supersaturation on Particle Size and Crystal Form 327 $a9.2 In-Line Mixing Crystallization 330 $aFilled with industrial examples emphasizing the practical applications of crystallization methodologies Based on the authors' hands-on experiences as process engineers at Merck, Crystallization of Organic Compounds guides readers through the practical aspects of crystallization. It uses plenty of case studies and examples of crystallization processes, ranging from development through manufacturing scale-up. The book not only emphasizes strategies that have been proven successful, it also helps readers avoid common pitfalls that can render standard procedures unsuccessful. The goal o 606 $aCrystallization$xIndustrial applications 606 $aPharmaceutical chemistry 606 $aPharmaceutical industry 615 0$aCrystallization$xIndustrial applications. 615 0$aPharmaceutical chemistry. 615 0$aPharmaceutical industry. 676 $a615/.19 686 $aVE 9500$2rvk 700 $aTung$b Hsien-Hsin$f1955-$01658856 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910816988403321 996 $aCrystallization of organic compounds$94013143 997 $aUNINA